Krystal Biotech (KRYS) Tests Its Multiproduct Story After Recent Pullback

Krystal Biotech (KRYS) has drawn fresh attention after recent trading left the stock about 9% lower over the past month, even as its year to date return remains firmly positive.

Recent trading suggests momentum in Krystal Biotech is fading in the short term, with the share price down about 9% over the past month and roughly 7% over the past quarter. This comes even though the year to date share price return is 26% and the 1 year total shareholder return is 67%.

Spot what might be the next Krystal Biotech style mover by scanning our hand picked list of 27 high quality undervalued stocks with strong cash flows and robust balance sheets.

Krystal Biotech has pulled back after a strong run, which leaves a simple tension. Does that recent slide improve the odds for new buyers, or is the easy money already gone as valuation stretches?

Most Popular Narrative: 20.6% Undervalued

Krystal Biotech last closed at $311.50, while the most followed narrative framework places fair value nearer $392.11 using a 7.5% discount rate. That gap reflects a view that the current share price does not fully capture the potential of Vyjuvek and the broader HSV 1 based pipeline.

Advancement of Krystal Biotech toward a multiproduct genetic medicines company through late stage programs such as KB803, KB801, KB407, KB111, KB707 and KB408, supported by HSV 1 platform technology designations, could broaden the revenue base beyond Vyjuvek and spread fixed costs across multiple products.

See why 34 investors see Krystal Biotech as 21% undervalued.

Result: Fair Value of $392.11 (UNDERVALUED)

Still, pricing pressure on Vyjuvek in Europe and higher HSV 1 platform spending could strain Krystal Biotech margins if new products scale more slowly than analysts model.

Find out about the key risks to this Krystal Biotech narrative.

Another View: Krystal Biotech Through The P/E Lens

The SWS DCF model flags Krystal Biotech as deeply undervalued, with the current $311.50 price sitting well below an estimated future cash flow value of $1,782.15. Yet on a P/E basis the stock trades at 38.2x, roughly double the US Biotechs industry on 18.8x and above the 33.1x fair ratio that the market could move toward over time. If sentiment swings back toward that lower multiple, how comfortable are you with the valuation risk that implies versus the upside the cash flow model suggests?

See what the numbers say about this price in our valuation breakdown, then compare it against how peers trade to pressure test your own view on Krystal Biotech, See what the numbers say about this price — find out in our valuation breakdown.

For a visual sense of how Krystal Biotech lines up against its sector on earnings based pricing, review the latest relative multiple snapshot,

Next Steps

Mixed messages in Krystal Biotech's story so far. Act while the data is fresh and pressure test the bullish and cautious arguments by reviewing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Krystal Biotech?

Do not stop at Krystal Biotech. Put fresh ideas on your radar now by running a quick screen and seeing which stocks actually fit your checklist today.

• Target potential mispricings by scanning a curated 27 high quality undervalued stocks that already combine solid cash flows with financial strength.
• Stack your portfolio with staying power by reviewing a list of solid balance sheet and fundamentals (25 results) that can better handle shocks when conditions turn.
• Hunt for off the radar opportunities by filtering through 21 high quality undiscovered gems before attention and liquidity move elsewhere.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com